# Addus HomeCare Corporation (ADUS)

**Exchange:** NASDAQ  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-27  
**Report type:** Primer (steps 1–3 of 19)  
**API endpoint:** GET /api/v1/research/ADUS/primer

## Business Model

---
source: coverage-next-full
ticker: ADUS
step: 01
title: Business Overview & Value Chain
generated: 2026-05-27
---

### Step 01 — Business Overview & Value Chain: Addus HomeCare Corporation (ADUS)

#### 1. Business Description

Addus HomeCare Corporation is a Frisco, Texas-based provider of home- and community-based services, operating three distinct segments that collectively serve patients across 21+ states. [S1] Founded in 1979 and public since 2009, the company has evolved from a primarily Illinois-based personal care agency into one of the largest independent multi-state home care platforms in the United States.

**Core Mission:** Enable medically complex and functionally limited individuals — predominantly elderly Medicaid/Medicare "dual eligibles" — to receive care in their homes rather than in higher-cost institutional settings (nursing homes, hospitals).

**FY2025 Revenue by Segment:**
| Segment | Revenue | % of Total | Key Payor |
|---------|---------|-----------|-----------|
| Personal Care | ~$1,100M est. | ~77% | Medicaid / HCBS / MCOs |
| Hospice | ~$213M est. | ~15% | Medicare / Medicaid |
| Home Health | ~$110M est. | ~8% | Medicare / MCOs |
| **Total** | **$1,423M** | **100%** | |

[S1: 10-K FY2025, Q1 2026 8-K]

#### 2. Three-Segment Business Model

##### Segment 1: Personal Care (Core Business, ~77% of Revenue)
- **Service:** Non-medical assistance with activities of daily living (ADLs): bathing, dressing, grooming, mobility assistance, light housekeeping, meal preparation, companionship
- **Consumers:** Predominantly elderly, disabled, or functionally limited individuals with Medicaid eligibility; heavily "dual eligible" (Medicare + Medicaid)
- **Employees:** Personal Care Aides (PCAs), Home Health Aides (HHAs) — paraprofessional, typically hourly, no clinical license required
- **Payor:** State Medicaid agencies directly, and increasingly Medicaid Managed Care Organizations (MCOs) that have assumed HCBS risk from states
- **Revenue model:** Hours of service delivered × contracted hourly rate (set by state or MCO contract)
- **Key geographies (FY2025):** Illinois (historic core, ~30-35% est.), Texas (expanded via Gentiva acquisition), Indiana, Ohio, Missouri, and 15+ other states

##### Segment 2: Hospice (~15% of Revenue)
- **Service:** End-of-life care for terminally ill patients (typically prognosis of ≤6 months); includes pain management, spiritual support, family counseling
- **Employees:** Registered nurses, social workers, chaplains, hospice aides — multidisciplinary team model
- **Payor:** Medicare Hospice Benefit (primary), Medicaid
- **Revenue model:** Per-diem rate × days enrolled (4 levels of care: routine home care, continuous home care, general inpatient, respite)
- **Regulatory note:** Medicare sets national per-diem rates; hospice election reduces other Medicare spending creating value for the payer

##### Segment 3: Home Health (~8% of Revenue)
- **Service:** Skilled nursing, physical therapy, occupational therapy, speech therapy — post-acute or chronic disease management
- **Employees:** Registered nurses, licensed physical/occupational/speech therapists
- **Payor:** Medicare, Medicare Advantage (MCOs), Medicaid
- **Revenue model:** Per-episode (PDGM under Medicare) or per-visit
- **Dynamics:** Subject to Medicare rate cuts; ADUS home health has been the softest segment in recent quarters [S2]

#### 3. Value Chain Layer Map

```
UPSTREAM (Referral & Contract)
├── State Medicaid Agencies → set HCBS rates, award contracts
├── Medicaid MCOs → negotiate per-member-per-month or hourly rates
├── Medicare → set hospice per-diems (national) + home health PDGM rates
├── Hospitals / SNFs / ACOs → discharge planning, referral source for home health + hospice
└── Physicians / Palliative Care teams → hospice order, home health order

MIDSTREAM (ADUS Operations)
├── Central Services: HR, recruitment, training, compliance, EVV technology
├── Branch Operations: ~250+ care centers across 21+ states
├── Caregiver Workforce: ~50,000+ personal care aides + clinical staff
├── Care Coordination: matching patients to caregivers, scheduling, quality monitoring
└── Billing & Collections: claims submission to state agencies/MCOs/Medicare

DOWNSTREAM (Consumer)
└── Patient/Consumer: elderly, dual-eligible, disabled individual at home
    ├── Outcome: avoid nursing home placement, reduce hospitalizations
    └── Value: ~60-80% cost reduction vs. institutional care
```

#### 4. Revenue Architecture (Unit Economics)

**Personal Care Unit Economics:**
- Revenue per hour: $20-25 (set by state Medicaid / MCO contracts; varies significantly by state)
- Caregiver wage: $15-19/hr (varies by state; minimum wage floors increasingly binding)
- Direct cost ratio: ~67% of revenue (caregiver wages + benefits + workers' comp)
- Gross margin: ~33% (net of caregiver costs)
- SG&A: ~23% of revenue (branch overhead, compliance, corporate)
- EBITDA margin: ~10-11%

**Hospice Unit Economics:**
- Average daily census: Growing; hospice per-diem from Medicare (FY2025 routine rate ~$228/day)
- ADUS hospice: Higher-margin segment than personal care (Medicare rates historically more stable)

**Home Health Unit Economics:**
- PDGM: 60-day episode payment varying by diagnosis + functional status; Medicare rate pressure ongoing

#### 5. Geographic Footprint
- **States served:** 21+ states across Midwest, Mid-Atlantic, South, and Southwest
- **Key states:** Illinois (personal care legacy), Texas (Gentiva expansion), Indiana, Ohio, Missouri, North Carolina, Georgia
- **New York:** Divested personal care operations in FY2025 due to CDPAP regulatory restructuring [S1]
- **Branch network:** ~250+ local care centers (branches)

#### 6. Customer Profile
- **Age:** Predominantly 65+; significant 75-85+ cohort
- **Functional status:** Require assistance with ≥2 ADLs; many have multiple chronic conditions
- **Payor status:** "Dual eligible" (Medicare + Medicaid) is the core; also Medicaid-only and Medicare-only
- **Key characteristic:** Sticky — consumers often stay with the same caregiver for years; high switching cost for patient

#### 7. Competitive Positioning Summary
- **Scale advantage:** Top-5 independent personal care provider nationally post-Gentiva
- **Technology:** EVV compliance, scheduling algorithms — operational efficiency vs. smaller independents
- **Managed care relationships:** Long-term MCO contracts create revenue visibility
- **Geographic density:** Key in Illinois/Midwest; building density in South/Southwest via acquisitions

#### Source Index
- [S1] 10-K FY2025 (filed 2026-02-24) — SEC EDGAR
- [S2] Q1 2026 Earnings (8-K, May 2026) — Stocktitan.net summary
- [S3] StockAnalysis.com ADUS Overview — stockanalysis.com/stocks/adus/

## Financial Snapshot

---
source: coverage-next-full
ticker: ADUS
step: 04
title: Financial Quality & Adversarial Sweep
generated: 2026-05-27
---

### Step 04 — Financial Quality & Adversarial Research Sweep: Addus HomeCare Corporation (ADUS)

#### 1. Financial Statement Quality Assessment

##### Revenue Recognition
- **Method:** Services delivered basis — revenue recognized when personal care hours are delivered, hospice days are served, or home health visits are completed [S1]
- **Quality:** HIGH. No complex arrangements, no percentage-of-completion, no deferred revenue structures. Service delivery is the single trigger.
- **EVV verification:** Electronic Visit Verification provides a real-time audit trail of care delivery, reducing billing disputes and fraud risk
- **Adjustments needed:** NONE significant. Revenue as reported is reliable.

##### Cost of Revenue
- Predominantly caregiver wages + benefits + workers' compensation insurance
- Payroll timing: Weekly/bi-weekly; no significant timing distortions
- Workers' comp: Self-insured to varying degrees by state; actuarial reserves reflect expected claims
- **Quality:** HIGH. Direct labor cost is straightforward to verify against payroll records.

##### Goodwill ($997M = 70% of total assets as of FY2025)
- Largest balance sheet item; reflects 20+ acquisitions over 10+ years
- Annual impairment testing required (ASC 350); no goodwill impairment charges recorded in FY2021-FY2025 [S1]
- **Risk:** If acquired businesses underperform (e.g., Gentiva integration fails), impairment charges could be material (~$100-300M non-cash write-down possible in adverse scenario)
- **Assessment:** Management has consistently delivered accretive acquisitions; goodwill level is elevated but supported by stable cash flows

##### Intangible Assets ($102M)
- Primarily customer relationships, non-compete agreements, and trade names acquired via M&A
- Amortized over useful lives (7-20 years typically for customer relationships)
- Annual amortization ~$15-17M; reduces GAAP earnings but not economic earnings
- **Adjusted EBITDA addback:** Amortization is legitimately added back to understand economic earnings

##### Deferred Revenue / Working Capital
- No significant deferred revenue
- Working capital: Accounts receivable ~$200-250M (Medicaid/Medicare — typically 45-90 day payment cycles)
- DSO (Days Sales Outstanding): ~60-75 days (typical for government payor); government is slower but reliable
- **Quality:** MEDIUM. Medicaid AR can be complex; some state-specific payment delays occur. No evidence of channel stuffing or premature revenue recognition.

##### Earnings Quality Score: **B+ (High Quality)**
- Core operations generate genuine cash flows: OCF/Net Income ratio ~1.15-1.2x (above 1.0 = good quality)
- SBC (~$18-20M/year) reduces cash compensation but is a real economic cost; GAAP earnings appropriately reflect this
- No significant one-time items manipulating reported results (integration costs disclosed separately as "non-cash" but cash is still deployed)

#### 2. Adjusted Earnings vs. GAAP Reconciliation (FY2025)

| Metric | GAAP | Adjustment | Adjusted |
|--------|------|-----------|---------|
| Net Income | $96M | — | $96M |
| Add: Amortization | — | +$16M | — |
| Add: SBC | — | +$18M | — |
| Add: D&A (ex-amortization) | — | +$5M | — |
| Less: Tax on addbacks | — | (~$9M) | — |
| **Adjusted EBITDA** | — | — | **~$155M** |
| **Adjusted EPS (est.)** | **$5.22** | +$1.30 adj. | **~$6.40-6.50** |

*Note: Management uses "Adjusted EPS" excluding amortization of acquired intangibles; Q1 2026 reported $1.62 adjusted EPS vs. $1.36 GAAP [S2]*

#### 3. Adversarial Research Sweep

**Methodology:** Searched for short-seller reports, regulatory investigations, class action lawsuits, whistleblower filings, and bearish institutional research. Transcript analysis not performed (coverage-next-full path).

##### Finding 1: No Active Short-Seller Reports
- No published short-seller thesis found (Hindenburg, Muddy Waters, Citron, etc.)
- Short interest: Modest; MarketBeat shows routine short interest without spike indicators [S3]
- Assessment: **Clean** — no organized short-side campaign targeting ADUS

##### Finding 2: New York CDPAP Divestiture (Regulatory Adverse Event)
- **What happened:** New York's Consumer Directed Personal Assistance Program (CDPAP) underwent restructuring in 2024-2025; state created a new fiscal intermediary (FI) model; ADUS determined its NY operations were no longer financially viable
- **Impact:** Divested NY personal care operations; revenue loss not disclosed but material enough to trigger divestiture; ADUS cited "changes and uncertainty in New York regarding the CDPAP" [S1]
- **Assessment:** RESOLVED — NY operations exited; no ongoing NY regulatory risk. Demonstrates that state regulatory changes CAN force business model exits. Bears cite this as evidence that reimbursement risk is real and not theoretical.

##### Finding 3: Medicaid Billing Compliance Risk
- Home health and hospice companies are perennial OIG targets for false claims and billing fraud
- ADUS 10-K discloses routine legal proceedings; no material OIG investigation or settlement found [S1]
- EVV mandate compliance reduces personal care billing abuse risk
- **Assessment:** LOW RISK — No material compliance issue identified; EVV reduces fraud exposure vs. pre-EVV era

##### Finding 4: OBBBA Medicaid Eligibility Restrictions
- "One Big Beautiful Bill Act" (Trump-era federal legislation) includes provisions limiting Medicaid eligibility (immigration status restrictions, work requirements)
- ADUS is exposed: If Medicaid rolls shrink, personal care census shrinks proportionally
- **Assessment:** ACTIVE RISK — Not a fraud concern but a legitimate business risk. Effect size uncertain; Congressional outcomes subject to change.

##### Finding 5: Insider Selling Pattern
- Multiple insiders sold shares over 2024-2025 via 10b5-1 plans [S4]
- No open-market buying documented in the same period
- **Assessment:** MILD YELLOW FLAG — Selling is routine (tax-driven) but absence of open-market buying reduces conviction signal from insiders. CEO's 1.6% stake ($16M at current price) is material but not dominant.

##### Finding 6: Goodwill Concentration / Acquisition Risk
- $997M goodwill on $1.43B revenue and $1.08B equity — balance sheet is goodwill-heavy
- Gentiva acquisition ($340M, closed 2024) is the largest single acquisition; integration still in progress [S1]
- **Assessment:** ONGOING RISK — Not a quality/fraud issue, but an execution risk. If Gentiva underperforms, non-cash impairment charges possible.

##### Finding 7: Labor Wage Pressure
- Caregiver wages are the dominant cost (67% of revenue); minimum wage increases in IL, TX, and other states create structural cost pressure
- **Assessment:** INDUSTRY-WIDE RISK — Not ADUS-specific; peers face identical dynamic. ADUS's scale and EVV efficiency somewhat mitigate vs. smaller players.

#### 4. Financial Statement Flags Summary

| Issue | Severity | Status |
|-------|---------|--------|
| Revenue recognition | Low | Clean; service delivery basis |
| Goodwill impairment risk | Medium | Active; Gentiva integration key |
| NY CDPAP exit | Medium | Resolved; demonstrates state risk |
| Medicaid billing compliance | Low | No active investigation |
| Insider selling | Low | Routine 10b5-1; not conviction-driven |
| OBBBA Medicaid cuts | Medium-High | Active; legislative uncertainty |
| Short-seller activity | None | No organized short campaign |

**Overall Financial Quality Rating: B+ / Low Concern**
Core business generates real cash flows; accounting is straightforward; principal risks are regulatory/political, not accounting-based.

#### 5. Quality Adjustments for Modeling
1. Use **Adjusted EBITDA** (~$155M FY2025) for valuation; add back amortization of acquired intangibles (~$16M)
2. Use **Adjusted EPS** for earnings power comparisons; adds back ~$0.90/share intangible amortization
3. Treat goodwill as a permanent asset for DCF purposes (no amortization under GAAP); test acquisition economics separately
4. FCF is the cleanest profitability measure: $104M FY2025 / $111M OCF after $8M CapEx

#### Source Index
- [S1] 10-K FY2025 (filed 2026-02-24) — SEC EDGAR
- [S2] Q1 2026 Earnings (8-K press release, May 2026) — via Stocktitan.net
- [S3] MarketBeat ADUS short interest — marketbeat.com/stocks/NASDAQ/ADUS/short-interest/
- [S4] SimplyWallSt — insider selling flag

## Recent Catalysts

---
source: coverage-next-full
ticker: ADUS
step: 12
title: Bull vs. Bear — Analyst Debate
generated: 2026-05-27
note: Transcript analysis NOT performed (coverage-next-full path). Bull/bear framing derived from SEC filings, press releases, consensus research, and news. 14 analysts cover ADUS (9 Strong Buy, 3 Buy, 1 Hold, 1 Sell) as of May 2026.
---

### Step 12 — Bull vs. Bear (Analyst Debate): Addus HomeCare Corporation (ADUS)

#### 1. Setup

**Current Price:** ~$93.50
**Analyst Average Price Target:** $132.69 (+42% upside implied)
**Price Target Range:** $92–$155
**Consensus:** 9 Strong Buy + 3 Buy + 1 Hold + 1 Sell (out of 14 analysts)

The debate is not whether ADUS is a good business — most analysts agree on the secular tailwind and quality of the franchise. The debate centers on:
1. The magnitude and timing of Medicaid funding risk from federal legislation
2. Whether the current stock price ($93.50) already discounts enough risk, or whether the risk is underappreciated
3. Whether the Gentiva acquisition creates a multi-year earnings growth engine or a temporary leverage/integration burden

[S1: StockAnalysis.com forecast; analyst consensus data]

#### 2. Bull Case — 3 Core Arguments

##### Bull 1: Secular Demographic Tailwind + HCBS Policy Expansion = Durable Volume Growth
The 85+ population (ADUS's core consumer cohort) grows 4%+ annually through 2035. Federal and state policy actively redirects Medicaid spend from nursing homes to lower-cost home settings. Every state ADUS operates in has an interest in expanding HCBS utilization — it saves them $50,000-100,000 per year per consumer versus nursing home placement. Personal care same-store growth has been a consistent 6-7% annually for 5+ years, through COVID, staffing shortages, and inflationary cycles. This is not cyclical demand; it is structural. [S2]

##### Bull 2: Gentiva Integration Creates a Multi-State Earnings Engine — FCF Power Severely Undervalued
The market is pricing ADUS on FY2025 GAAP earnings ($5.22 EPS → 18x P/E). But GAAP earnings are penalized by $0.90+ in amortization of acquired intangibles (non-cash, purely accounting) and elevated integration costs from Gentiva. Adjusted EPS is ~$6.50 and on consensus trajectory to reach $7.07 in FY2026. FCF/share on a TTM basis is $7.35 — making ADUS's ~13x FCF yield at $93.50 exceptionally cheap relative to the growth rate. As debt approaches zero (Q3-Q4 2026), the FCF all flows to continued M&A or potential shareholder returns. The "earn-out" from Gentiva (margin improvement as IL-level margins are applied to the acquired Texas operations) has years to run. [S3, S4]

##### Bull 3: Valuation Discount Is Unjustified — ADUS Should Re-Rate to 12-14x EBITDA
ADUS trades at ~11x TTM EBITDA and ~12x forward EBITDA ($93.50 + $36M net debt ≈ $1.79B EV; $155M FY2025 EBITDA = 11.5x). Pennant Group (PNTG) — a smaller, less geographically diversified home health/hospice company — trades at 15-18x EBITDA. The Barclays downgrade (target $92) reflects short-term Medicare/Medicaid anxiety; but the actual EBITDA trajectory continues improving (Q1 2026 +9.7% YoY). At 13x FY2026E EBITDA of $175M ($155M × 13% growth), ADUS is worth ~$140-150/share — consistent with the 12 Buy analysts' average target of ~$138. A re-rating catalyst emerges when Gentiva integration is pronounced complete and same-store margins normalize. [S1]

#### 3. Bear Case — 3 Core Arguments

##### Bear 1: Medicaid Funding Cuts Are Real and Could Be Severe
The OBBBA is not theoretical risk — it includes specific Medicaid eligibility restrictions (immigration status, work requirements) that CBO projects could reduce Medicaid enrollment by 7-10 million people. For a company deriving 77% of revenue from Medicaid personal care, even a 5% enrollment reduction is a $55M revenue headwind and $18M EBITDA hit. Combine this with the proposed 80/20 compensation rule (which could compress gross margins by 200-300bp if states don't offset with rate increases), and ADUS's EBITDA could be flat or declining in FY2027 instead of growing. The market is too sanguine about Medicaid structural risk; the NY CDPAP exit showed that state-level changes CAN force a business exit. [S5]

##### Bear 2: Labor Cost Inflation Will Eventually Catch Up to Rate Increases
The FY2021-FY2025 gross margin expansion (+130bp) happened during a period when state Medicaid rate increases kept pace with caregiver wage floors. But Illinois minimum wage continues rising, and the structural caregiver shortage means wage premiums above minimum wage are necessary to attract and retain workers. If caregiver wages rise 4-5% annually but Medicaid rates rise only 2-3%, ADUS's gross margin compresses 100-200bp. At 30.5-31% gross margin (down from 32.5%), EBITDA drops from $155M to ~$125-135M — a multiple compression scenario that could drive the stock below $80. Barclays set its target at $92 reflecting this risk. [S5]

##### Bear 3: Post-Gentiva, Growth Has Structurally Slowed to 7-8% — Doesn't Justify Current Multiple
Q1 2026 organic revenue growth was +7.7%, slowing from 20-25% YoY comps when Gentiva was consolidating. The "true" organic growth rate is 6-8% annually — fine, but not exceptional. ADUS is now a $1.4B revenue company growing 8% organically; the market must decide whether it deserves a growth premium or a "steady state" multiple. If ADUS de-rates from 11x to 9x EBITDA (reflecting the transition from "acquisitive growth" to "mature compounder"), the stock could trade at $75-80 even on $155M EBITDA. The home health segment (8% of revenue) is a drag — no clear catalyst for improvement. Meanwhile, the Barclays sell-side downgrade signals that institutional conviction is not universal. [S1, S5]

#### 4. Key Debate Questions

| Question | Bull Answer | Bear Answer |
|---------|-----------|-----------|
| Will OBBBA cuts be severe for ADUS? | No — HCBS is politically protected; states will resist | Yes — structural enrollment reduction already legislated |
| Is Gentiva integration complete? | On track — debt paid down; margins improving | Too early — full margin normalization 2+ years away |
| What's the right EBITDA multiple? | 13-15x (growth compounder) | 9-10x (regulated utility with capitation risk) |
| Can same-store growth sustain 6%+? | Yes — demographics are the floor | Uncertain — NY exit shows state risk is material |
| Will home health recover? | Immaterial — ADUS pivoting away | Drag on consolidated results; shows regulatory exposure |

#### 5. Resolution Catalysts

**Events that would resolve the debate in bulls' favor:**
- FY2026 guidance raise with EBITDA above $170M
- OBBBA Medicaid provisions weakened in Congressional compromise
- Gentiva geographic markets showing same-store growth catch-up to legacy ADUS
- Debt-free balance sheet achieved → announces buyback program
- Acquisition of a hospice/home health business at accretive multiple

**Events that would resolve the debate in bears' favor:**
- OBBBA passes with full Medicaid restrictions → enrollment data shows 5%+ decline
- Illinois announces a Medicaid rate freeze for FY2026
- Q2 or Q3 2026 earnings miss on both revenue and EBITDA
- Goodwill impairment on any segment
- Caregiver wage settlement materially above current accruals

---

#### Bull Case — Summary (3 bullets)
1. **Secular tailwind is structural:** Demographics + HCBS policy expansion = durable 6-7% organic personal care volume growth; same-store has never gone negative in 5 years
2. **Severely undervalued on FCF:** $7.35 FCF/share at $93.50 = 12.7x FCF yield; approaching net-zero debt means all FCF available for M&A or buybacks — value creation accelerates
3. **Gentiva integration is working:** Debt down $180M in 12 months post-close; Q1 2026 personal care metrics on target; multi-state earnings engine becoming self-evident

#### Bear Case — Summary (3 bullets)
1. **Medicaid funding at structural risk:** OBBBA eligibility restrictions + 80/20 wage rule = potential 200-400bp EBITDA margin compression; NY CDPAP showed market-exit risk is real
2. **Valuation requires perfect execution:** At $93.50, stock prices in ~$7 EPS with no margin cushion; any guidance miss or EBITDA miss re-rates the stock to 9-10x EBITDA = $75-85 range
3. **Labor cost structure is a ceiling, not a floor:** Caregiver shortage + minimum wage escalation will eventually overwhelm rate pass-through; gross margin expansion was the anomaly, compression is the mean-reversion

#### Source Index
- [S1] StockAnalysis.com ADUS Forecast — analyst consensus, price targets
- [S2] Industry + demographic research (Steps 02, 11)
- [S3] Cash flow analysis (Steps 05-07)
- [S4] Q1 2026 earnings release (8-K, May 2026) — Stocktitan.net
- [S5] SimplyWallSt news analysis — OBBBA risk, Barclays downgrade, insider selling

## Full Research Available

This primer covers steps 1–3 of 19. The full deep dive (moat analysis, DCF, bull/bear,
management quality, earnings transcript analysis) is available via:

- Investment memo: /memo/adus
- Full research API: GET /api/v1/research/ADUS/memo
- Coverage universe: /stocks